TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026)
TerrAscend's (TSNDF) quarterly Cash from Discontinued Operations came in at 165000.0 in Q1 2026, up 94.8% year-on-year from 84701.6 in Q1 2025, and up 47.28% on a QoQ basis from 313000.0 in Q4 2025.
TerrAscend (TSNDF) Cash from Discontinued Operations (2022 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 5 years of Cash from Discontinued Operations data on file, last reported at 165000.0 in Q1 2026.
- On a quarterly basis, Cash from Discontinued Operations rose 94.8% year-over-year to 165000.0 in Q1 2026; TTM through Mar 2026 was 9389000.0, a 17.93% increase from a year earlier, with the FY2025 full-year figure at 12398000.0, down 49.99% from the prior year.
- Cash from Discontinued Operations for Q1 2026 stood at 165000.0, up from 313000.0 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for TSNDF reached as high as 2956000.0 in Q4 2024 and fell as low as 20757000.0 in Q4 2023.
- Historically, Cash from Discontinued Operations has averaged 3095875.0 across 5 years, with a median of 1646500.0 in 2022.
- Across the five-year window, Cash from Discontinued Operations sank 9378.08% in 2023 and surged 114.24% in 2024, its largest moves.
- Year by year, Cash from Discontinued Operations stood at 219000.0 in 2022, then sank by 9378.08% to 20757000.0 in 2023, then jumped by 114.24% to 2956000.0 in 2024, then slumped by 110.59% to 313000.0 in 2025, then surged by 47.28% to 165000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Discontinued Operations figures were 165000.0 in Q1 2026, 313000.0 in Q4 2025, and 4427000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.84 Bn | 32.10 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.67 Bn | 30.73 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.69 Bn | 23.63 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.12 Bn | 20.97 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.24 Bn | 18.44 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.83 Bn | 16.51 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.64 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | TerrAscend | 157.69 Mn | 157.22 Mn | 34.60 Mn | -165,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -165,000.00 |
| Mar 31, 2026 | -165,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Dec 31, 2025 | -313,000.00 |
| Sep 30, 2025 | -4.43 Mn |
| Sep 30, 2025 | -4.43 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Jun 30, 2025 | -4.48 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Mar 31, 2025 | -3.17 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Dec 31, 2024 | 2.96 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Jun 30, 2024 | -7.18 Mn |
| Dec 31, 2023 | -20.76 Mn |
| Dec 31, 2023 | -20.76 Mn |
| Sep 30, 2023 | -496,000.00 |
| Sep 30, 2023 | -496,000.00 |